Hypothyroidism Market Report and Forecast 2025-2034
Description
The hypothyroidism market size was valued at USD 2.10 Billion in 2024 in the 7 major markets, driven by the rising incidence of thyroid gland disorders. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2025-2034, with the values likely to reach USD 3.29 Billion by 2034.
Hypothyroidism: Introduction
Hypothyroidism, also known as underactive thyroid, occurs when the thyroid gland produces less thyroid hormone than needed by the body. This condition is commonly diagnosed by blood tests. Symptoms vary from person to person, depending on the severity. Common symptoms include weight gain, tiredness, dry skin, sensitivity to cold, constipation among others. Thyroid hormone medicines are frequently used as a treatment for the condition.
Hypothyroidism Market Analysis
The hypothyroidism market demand has increased with the increasing incidence of Hashimoto's Thyroiditis, which is an autoimmune disorder impacting the thyroid gland and causing hypothyroidism.
While levothyroa, the synthetic form of T4 hormone, is the most prescribed thyroid medicine, there has been focus on developing other effective medicines as well. Selenium supplements and thyroid hormone analogs, which help in hormone deficiency compensation and corticosteroids, are emerging as potential treatment alternatives in the market. Desiccated thyroid extract (DTE), a natural blend of thyroid hormone containing both T3 and T4, has shown positive results in trials.
Apart from drug administration, there have been significant developments to treat the condition on the cellular level. In September 2023, Sernova Corp., a clinical-stage cell therapeutics company, unveiled a new cell therapy platform called the ‘Cell Pouch System’ to treat post operative hypothyroidism. Reimplantation of the thyroid tissue into the pre-vascularized Cell Pouch™ led to restoration of the thyroid hormones. The arrival of such technologies demonstrates that the hypothyroidism market value is projected to grow in the forecast period.
Hypothyroidism Market Segmentation
“Hypothyroidism Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Hypothyroidism affects approximately 5% of the global population with women being at a higher risk of getting affected. In the historical period, the United States has held a substantial part of the hypothyroidism market share. The increasing innovations in the medical field due to the existence of healthcare companies and research institutions, has largely contributed to the market growth.
Europe is also leading the market with the help of significant initiatives taken by the government to spread awareness on early recognition of the disease. The region has a well-equipped healthcare infrastructure to support the rising medical demands owing to the geriatric population. Major mergers and acquisitions between influential pharmaceutical and MedTech companies are impacting the market positively.
Similar trend can be observed in the Asia Pacific region, that has been undergoing significant hypothyroidism market growth. In May 2023, IBSA launched an international campaign called “Feel Thyroid” to promote greater knowledge and understanding of the symptoms. The campaign aimed at improving communication between doctors and patients to identify the most apt therapeutic treatment for the patients. Moreover, increasing privatization in the healthcare sector is also expected to foster growth with several companies stepping in to develop effective therapeutics.
Hypothyroidism Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Hypothyroidism: Introduction
Hypothyroidism, also known as underactive thyroid, occurs when the thyroid gland produces less thyroid hormone than needed by the body. This condition is commonly diagnosed by blood tests. Symptoms vary from person to person, depending on the severity. Common symptoms include weight gain, tiredness, dry skin, sensitivity to cold, constipation among others. Thyroid hormone medicines are frequently used as a treatment for the condition.
Hypothyroidism Market Analysis
The hypothyroidism market demand has increased with the increasing incidence of Hashimoto's Thyroiditis, which is an autoimmune disorder impacting the thyroid gland and causing hypothyroidism.
While levothyroa, the synthetic form of T4 hormone, is the most prescribed thyroid medicine, there has been focus on developing other effective medicines as well. Selenium supplements and thyroid hormone analogs, which help in hormone deficiency compensation and corticosteroids, are emerging as potential treatment alternatives in the market. Desiccated thyroid extract (DTE), a natural blend of thyroid hormone containing both T3 and T4, has shown positive results in trials.
Apart from drug administration, there have been significant developments to treat the condition on the cellular level. In September 2023, Sernova Corp., a clinical-stage cell therapeutics company, unveiled a new cell therapy platform called the ‘Cell Pouch System’ to treat post operative hypothyroidism. Reimplantation of the thyroid tissue into the pre-vascularized Cell Pouch™ led to restoration of the thyroid hormones. The arrival of such technologies demonstrates that the hypothyroidism market value is projected to grow in the forecast period.
Hypothyroidism Market Segmentation
“Hypothyroidism Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Levothyroxine
- Liothyronine
- Oral
- Parenteral
- Others
- Wholesale Distribution
- Retail Stores
- Online Pharmacy
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
Hypothyroidism affects approximately 5% of the global population with women being at a higher risk of getting affected. In the historical period, the United States has held a substantial part of the hypothyroidism market share. The increasing innovations in the medical field due to the existence of healthcare companies and research institutions, has largely contributed to the market growth.
Europe is also leading the market with the help of significant initiatives taken by the government to spread awareness on early recognition of the disease. The region has a well-equipped healthcare infrastructure to support the rising medical demands owing to the geriatric population. Major mergers and acquisitions between influential pharmaceutical and MedTech companies are impacting the market positively.
Similar trend can be observed in the Asia Pacific region, that has been undergoing significant hypothyroidism market growth. In May 2023, IBSA launched an international campaign called “Feel Thyroid” to promote greater knowledge and understanding of the symptoms. The campaign aimed at improving communication between doctors and patients to identify the most apt therapeutic treatment for the patients. Moreover, increasing privatization in the healthcare sector is also expected to foster growth with several companies stepping in to develop effective therapeutics.
Hypothyroidism Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc.
- Merck & Co.
- Lannett Company, Inc.
- Allergan plc
- Mylan N.V.
- GlaxoSmithKline plc
- Novartis AG
- RLC LABS
- Abbott Laboratories
- Viatris
- Elexis
- IBSA Pharma
- Amgen
- Fresenius SE and Co.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Hypothyroidism Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Hypothyroidism Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.3.2 France Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Hypothyroidism Epidemiology Forecast (2018-2034)
- 5.4 Japan Hypothyroidism Epidemiology Forecast (2018-2034)
- 6 Hypothyroidism Market Overview – 7MM
- 6.1 Hypothyroidism Market Historical Value (2018-2024)
- 6.2 Hypothyroidism Market Forecast Value (2025-2034)
- 7 Hypothyroidism Market Landscape – 7MM
- 7.1 Hypothyroidism: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Hypothyroidism Product Landscape
- 7.2.1 Analysis by Drug
- 7.2.2 Analysis by Route of Administration
- 8 Hypothyroidism Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Hypothyroidism Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Hypothyroidism Market Segmentation – 7MM
- 11.1 Hypothyroidism Market by Drug
- 11.1.1 Market Overview
- 11.1.2 Levothyroxine
- 11.1.3 Liothyronine
- 11.2 Hypothyroidism Market by Route of Administration
- 11.2.1 Market Overview
- 11.2.2 Oral
- 11.2.3 Parenteral
- 11.2.4 Others
- 11.3 Hypothyroidism Market by Distribution Channel
- 11.3.1 Market Overview
- 11.3.2 Wholesale Distribution
- 11.3.3 Retail Stores
- 11.3.4 Online Pharmacy
- 11.4 Hypothyroidism Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Hypothyroidism Market
- 12.1 Hypothyroidism Market Historical Value (2018-2024)
- 12.2 Hypothyroidism Market Forecast Value (2025-2034)
- 12.3 Hypothyroidism Market by Disease Type
- 12.4 Hypothyroidism Market by Treatment Type
- 13 EU-4 and United Kingdom Hypothyroidism Market
- 13.1 Hypothyroidism Market Historical Value (2018-2024)
- 13.2 Hypothyroidism Market Forecast Value (2025-2034)
- 13.3 Germany Hypothyroidism Market Overview
- 13.3.1 Hypothyroidism Market by Disease Type
- 13.3.2 Hypothyroidism Market by Treatment Type
- 13.4 France Hypothyroidism Market Overview
- 13.4.1 Hypothyroidism Market by Disease Type
- 13.4.2 Hypothyroidism Market by Treatment Type
- 13.5 Italy Hypothyroidism Market Overview
- 13.5.1 Hypothyroidism Market by Disease Type
- 13.5.2 Hypothyroidism Market by Treatment Type
- 13.6 Spain Hypothyroidism Market Overview
- 13.6.1 Hypothyroidism Market by Disease Type
- 13.6.2 Hypothyroidism Market by Treatment Type
- 13.7 United Kingdom Hypothyroidism Market Overview
- 13.7.1 Hypothyroidism Market by Disease Type
- 13.7.2 Hypothyroidism Market by Treatment Type
- 14 Japan Hypothyroidism Market
- 14.1 Hypothyroidism Market Historical Value (2018-2024)
- 14.2 Hypothyroidism Market Forecast Value (2025-2034)
- 14.3 Hypothyroidism Market by Disease Type
- 14.4 Hypothyroidism Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 AbbVie Inc.
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Merck & Co.
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Lannett Company, Inc.
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Allergan plc
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Mylan N.V.
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 GlaxoSmithKline plc
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 Novartis AG
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 RLC LABS
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 Abbott Laboratories
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Viatris
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Elexis
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 IBSA Pharma
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Amgen
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Fresenius SE and Co.
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 21 Hypothyroidism Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
